Michael J. Bruner Ph.D.

Partner

Atlanta + 1.404.581.8614

Connect:

Share

Dr. Michael Bruner's practice focuses on patent preparation and prosecution, with more than 20 years of experience representing clients in biotechnology, pharmaceutical, and chemical intellectual property matters, such as the development of global patent portfolios to protect their innovations. He guides clients from the early stages of patent portfolio development when leads are initially identified, continuing through the product development process as new filing opportunities arise.

Michael has a Ph.D. in organic chemistry and has extensive experience with patent matters pertaining to chemistry, biochemistry, and pharmaceuticals.

A particular focus of his practice is advising clients with respect to patent life cycle strategies and regulatory extension opportunities as the portfolio matures and regulatory approval approaches. He also advises clients on due diligence matters, including those relating to clients' investment in or acquisition of third parties, as well as licensing and collaboration opportunities.

A further aspect of Michael's practice is providing clients with opinions relating to patentability, freedom-to-operate, noninfringement, and validity.

Representative clients include Bristol Myers Squibb, Celgene Corporation, PTC Therapeutics, Hope Pharmaceuticals, Invirsa, Inc., Puma Biotechnology, Merck & Co., and Rigel Pharmaceuticals. Particular small molecule pharmaceuticals that Michael has been involved with include REVLIMID®, POMALYST®, NERLYNX®, Translarna ™, TAVALISSE®, REZLIDHIA®, and COPIKTRA®. In particular, Michael has been involved with the preparation and prosecution of various patent filings relating to the compounds, as well as applications for U.S. and foreign regulatory extensions.

Prior to attending law school, Michael performed postdoctoral research at the Centers for Disease Control and Prevention (CDC) in the areas of vaccine and infectious diseases.

Experience

  • Rigel develops global patent portfolio related to small molecule inhibitors for treatment of hematological and oncological conditionsJones Day is representing Rigel Pharmaceuticals, Inc. ("Rigel") in connection with the management of global patent portfolios related to TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult chronic immune thrombocytopenia, REZLIDHIA® (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia, GAVRETO® (pralsetinib) for the treatment of rearranged during transfection (RET) fusion-positive non-small cell lung cancer and thyroid cancer, and IRAK1/4 inhibitors for the treatment of inflammatory conditions.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Hope Pharmaceuticals develops global patent portfolio relating to highly purified forms of sodium nitrite and sodium thiosulfateJones Day represents Hope Pharmaceuticals in the establishment of a global patent portfolio related to highly purified forms of sodium nitrite and sodium thiosulfate relating to its FDA-approved cyanide antidote NITHIODOTE®.
  • PTC Therapeutics develops global patent portfolio for small molecule therapeuticsJones Day represents PTC Therapeutics, Inc. in the establishment of a global patent portfolio related to nonsense mutation suppressor TRANSLARNA® for the treatment of Duchenne Muscular Dystrophy ("DMD") and alternative splicing compounds for the treatment of Spinal Muscular Atrophy ("SMA").
  • Georgia-Pacific faces Nat'l Gypsum parent in DJ action over wallboardsJones Day represented Georgia-Pacific Gypsum LLC against New NGC in a declaratory judgment action alleging patent infringement and antitrust claims relating to glass mat-faced gypsum wallboards.
  • Danske Markets and Handelsbanken Capital Markets act as placement agent in €59.3 million rights offering by Danish biopharmaceutical companyJones Day advised Danske Markets and Handelsbanken Capital Markets in a €59.3 million (US$78.4 million) rights offering by LifeCycle Pharma A/S, a Danish biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen.
  • Symphony Capital forms joint venture with Lexicon PharmaceuticalsJones Day advised Symphony Capital Partners, L.P., and its co-investors in connection with a collaborative development agreement with Lexicon Pharmaceuticals, Inc. to establish a joint venture, Symphony Icon Inc. Symphony will provide $65 million in funding to accelerate clinical and other related development activities for three of Lexicon's product candidates: LX6171 for cognitive disorders, LX1031 for irritable bowel syndrome and LX1032 for gastrointestinal disorders.
  • Nordson acquires Kreyenborg Group's polymer processing companiesJones Day advised Nordson Corporation in its acquisition of Kreyenborg GmbH and BKG Bruckmann & Kreyenborg Granuliertechnik GmbH companies.
    • View All

    OCTOBER 2025 Commentary

    Federal Circuit Clarifies Limits on Patentability of Clinical Study Results-Based Applications

    JANUARY 2025 Alert

    USPTO Launches Significant Patent Fee Increases

    December 2014 Commentary

    First PTAB Decisions in Derivation Proceedings

    Additional Publications

    • 2003
      Evaluation of Synthetic, M type-specific Peptides as Antigens in a Multivalent Group A Streptococcal Vaccine, coauthor, Vaccine 21:2698
    • May 2001
      Multivalent Peptide Vaccine Against Group A Strep M Proteins Looks Promising, coauthor, Reuters Medical News
    • 2000
      Use of an Altered Nucleotide Substrate to Unmask the Transition-State for Rat Liver a(2-6) Sialyltransferase, coauthor, Biochemistry 39:2261
    • 1998
      Isotope Trapping and Kinetic Isotoope Effect Studies of Rat Liver a(2-6) Sialyltransferase, coauthor, Biochemistry 37:289
    • 1998
      The N-Acetyl Neuraminyl Oxocarbenium Ion is an Intermediate in the Presence of Anionic Nucleophiles, coauthor, J. Am. Chem. Soc. 120:1357
    • 1996
      Acid-Catalyzed Solvolysis of CMP-NeuAc: Evidence for a Sialyl Cation with a Finite Lifetime, coauthor, J. Am. Chem. Soc. 118:10371

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.